Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Digi International Inc. (DGII) - free report >>
Palatin Technologies, Inc. (PTN) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Digi International Inc. (DGII) - free report >>
Palatin Technologies, Inc. (PTN) - free report >>
Image: Bigstock
New Strong Sell Stocks for March 11th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Digi International Inc. (DGII - Free Report) provides business and mission-critical Internet of Things products, services, and solutions. The Zacks Consensus Estimate for its current year earnings has been revised 9.5% downward over the last 30 days.
Independence Realty Trust, Inc. (IRT - Free Report) is a real estate investment trust that owns and operates multifamily apartment properties. The Zacks Consensus Estimate for its current year earnings has been revised 3.6% downward over the last 30 days.
IVERIC bio, Inc. is a biopharmaceutical company that develops novel therapies to treat ophthalmic diseases. The Zacks Consensus Estimate for its current year earnings has been revised 4% downward over the last 30 days.
Palatin Technologies, Inc. (PTN - Free Report) is a specialized biopharmaceutical company that develops targeted receptor-specific therapeutics for the treatment of various diseases. The Zacks Consensus Estimate for its current year earnings has been revised 55.6% downward over the last 30 days.
VistaGen Therapeutics, Inc. (VTGN - Free Report) is a clinical-stage biopharmaceutical company that engages in developing and commercializing various medicines. The Zacks Consensus Estimate for its current year earnings has been revised 21.1% downward over the last 30 days.
View the entire Zacks Rank #5 List.